Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
137.75
+8.65 (6.70%)
At close: Feb 21, 2025, 4:00 PM
138.95
+1.20 (0.87%)
After-hours: Feb 21, 2025, 6:21 PM EST
Axsome Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 385.69 | 270.6 | 50.04 | - | - | |
| Revenue Growth (YoY) | 42.53% | 440.80% | - | - | - | |
| Cost of Revenue | 33.3 | 26.07 | 4.1 | - | - | |
| Gross Profit | 352.39 | 244.54 | 45.94 | - | - | |
| Selling, General & Admin | 411.36 | 323.12 | 159.25 | 66.65 | 28.9 | |
| Research & Development | 187.08 | 97.94 | 57.95 | 58.06 | 70.19 | |
| Operating Expenses | 604.83 | 427.44 | 221.34 | 124.71 | 99.09 | |
| Operating Income | -252.44 | -182.91 | -175.4 | -124.71 | -99.09 | |
| Interest Expense | -6.57 | -6.45 | -7.34 | -5.7 | -2.57 | |
| EBT Excluding Unusual Items | -259.01 | -189.36 | -182.74 | -130.4 | -101.65 | |
| Merger & Restructuring Charges | - | - | -1.1 | - | - | |
| Other Unusual Items | -28.12 | -48.92 | -3.3 | - | -1.25 | |
| Pretax Income | -287.13 | -238.28 | -187.13 | -130.4 | -102.9 | |
| Income Tax Expense | 0.09 | 0.96 | - | - | - | |
| Net Income | -287.22 | -239.24 | -187.13 | -130.4 | -102.9 | |
| Net Income to Common | -287.22 | -239.24 | -187.13 | -130.4 | -102.9 | |
| Shares Outstanding (Basic) | 48 | 45 | 41 | 38 | 37 | |
| Shares Outstanding (Diluted) | 48 | 45 | 41 | 38 | 37 | |
| Shares Change (YoY) | 5.48% | 11.73% | 8.07% | 1.11% | 9.37% | |
| EPS (Basic) | -5.99 | -5.27 | -4.60 | -3.47 | -2.77 | |
| EPS (Diluted) | -5.99 | -5.27 | -4.60 | -3.47 | -2.77 | |
| Free Cash Flow | -128.68 | -145.66 | -117.21 | -108.53 | -78.5 | |
| Free Cash Flow Per Share | -2.69 | -3.21 | -2.88 | -2.89 | -2.11 | |
| Gross Margin | 91.37% | 90.37% | 91.81% | - | - | |
| Operating Margin | -65.45% | -67.59% | -350.54% | - | - | |
| Profit Margin | -74.47% | -88.41% | -373.99% | - | - | |
| Free Cash Flow Margin | -33.36% | -53.83% | -234.25% | - | - | |
| EBITDA | -244.48 | -176.07 | -171 | -124.63 | -99.06 | |
| EBITDA Margin | -63.39% | -65.07% | - | - | - | |
| D&A For EBITDA | 7.96 | 6.83 | 4.4 | 0.08 | 0.02 | |
| EBIT | -252.44 | -182.91 | -175.4 | -124.71 | -99.09 | |
| EBIT Margin | -65.45% | -67.59% | - | - | - | |
| Revenue as Reported | 385.69 | 270.6 | 50.04 | - | - | |
| Advertising Expenses | 101.2 | 100.3 | 35.3 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.